BioNotebook: Sangamo/Biogen, Adamas/Forest, Zymeworks/Lilly, Sunesis

 
• By Mandy Jackson

Sangamo gains 38% on Biogen license deal; Adamas collects $40m from Forest; Zymeworks inks deal with Lilly's Imclone, raises $15m; and Sunesis regains assets from Biogen, Millennium.

More from Anticancer

More from Therapy Areas